Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2

Record operating revenues of $5.404 billion for the fourth quarter, 4% higher year over year. -- Record operating revenues of $22.255 billion for the full year 2024, 2% higher year over year. -- Purchased and cancelled all 35,

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for